- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927.
- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer's disease.
Clear
All
Quotes
News
Learn
Help
All
US
HK
CN
SG
AU
JP
All
News
Announcements
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
Vigil Neuroscience Presented Data Highlighting Its Oral Small Molecule Program, Including Its Lead Clinical Candidate VG-3927, In Two Oral Presentations At The AD/PD 2025 International Conference On Alzheimer's And Parkinson's Diseases
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Like
1
Views 308
Write a comment
1
Comment(0)
Reason For Report